Management of cytotoxic chemotherapy-induced hand-foot syndrome
Improvements in systemic cancer treatments have resulted in more patients surviving for prolonged periods of time on treatment. This has made treatment-related toxicity and quality of life concerns increasingly relevant. Hand-foot syndrome (HFS) is a common skin reaction to systemic therapy that sh...
Main Authors: | Johannes J.M. Kwakman, Yannick S. Elshot, Cornelis J.A. Punt, Miriam Koopman |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2020-05-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | https://www.oncologyreviews.org/index.php/or/article/view/442 |
Similar Items
-
Atypical case of hand foot syndrome due to pegylated liposomal doxorubicin presenting as hyperpigmentation
by: Manjeet Naresh Ramteke, et al.
Published: (2015-01-01) -
Docetaxel-induced hand and foot syndrome in a patient with metastatic breast carcinoma
by: Ravichandran Gurumurthi, et al.
Published: (2013-01-01) -
Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin
by: Hu X, et al.
Published: (2021-01-01) -
Palmar-Plantar Erythrodysesthesia Associated with Chemotherapy and Its Treatment
by: Katherina Podlekareva Farr, et al.
Published: (2011-04-01) -
TEYSUNO: FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH DISSEMINATED GASTRIC CANCER
by: O. O. GORDEEVA, et al.
Published: (2017-06-01)